Gastrointestinal Cancer

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Despite some success stories, most gastrointestinal cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.

John L. Marshall, MD, reflects on recent advances in the field of metastatic colorectal cancer and discusses ongoing research efforts in the space.

Manish A. Shah, MD, discusses how the management of patients with gastric/GEJ cancer has evolved over the last several years.

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Amit G. Singal, MD, discusses systemic therapies in hepatocellular carcinoma.

Cholangiocarcinoma is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results.

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.